Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2990|44|1|91-111

ISSN： 0305-1846

Source： NEUROPATHOLOGY & APPLIED NEUROBIOLOGY, Vol.44, Iss.1, 2018-02, pp. : 91-111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence

By  

Reviews on Recent Clinical Trials, Vol. 13, Iss. 1, 2018-01 ,pp. : 61-68

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Medication Targets for the Treatment of Alcoholism: Preclinical Studies

By  

Recent Patents on CNS Drug Discovery, Vol. 7, Iss. 2, 2012-08 ,pp. : 151-162

Bentham Science Publishers

Access to resources Recommend Favorite

GABA‐modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence

By  

PHYTOTHERAPY RESEARCH, Vol. 32, Iss. 1, 2018-01 ,pp. : 3-18

John Wiley & Sons Inc

Access to resources Recommend Favorite

Petasins in the Treatment of Allergic Diseases: Results of Preclinical and Clinical Studies

By  

International Archives of Allergy and Immunology, Vol. 129, Iss. 2, 2002-10 ,pp. : 108-112

Karger

Access to resources Recommend Favorite

Review: Neurodegenerative processes in temporal lobe epilepsy with hippocampal sclerosis: Clinical, pathological and neuroimaging evidence

By  

NEUROPATHOLOGY & APPLIED NEUROBIOLOGY, Vol. 44, Iss. 1, 2018-02 ,pp. : 70-90

John Wiley & Sons Inc

Access to resources Recommend Favorite